Acerus is currently focusing its development efforts on creating new best-in-class versions of existing pharmaceutical compounds utilizing our novel nasal delivery platform.

Acerus applies proprietary drug delivery technology platforms to existing molecules, to create innovative products that improve the patient experience. It is intended that these drug delivery technologies provide a safer, possibly more effective and more practical solution for drug administration than competitive products on the market, with application across various therapeutic areas.

Acerus has licensed the rights to a proprietary platform based on a nasal gel technology that is currently used with NATESTO®. Acerus is pursuing the development and application of this technology to several high value pharmaceutical compounds, including, early stage research toward the development of prescription nasal cannabinoids using a similar technology.